Prestige Consumer Healthcare Inc
NYSE:PBH
Prestige Consumer Healthcare Inc
NYSE:PBH
Price:
70.39 USD
0.1%
Market Closed
Updated:
May 13, 2024
Prestige Consumer Healthcare Inc
Cash Equivalents
|
Prestige Consumer Healthcare Inc
Cash Equivalents Peer Comparison
Comparables:
JNJ
BMY
PFE
MRK
LLY
Competitive Cash Equivalents Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Prestige Consumer Healthcare Inc
NYSE:PBH
|
Cash Equivalents
$63.6m
|
CAGR 3-Years
1%
|
CAGR 5-Years
21%
|
CAGR 10-Years
-4%
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Cash Equivalents
$3.8B
|
CAGR 3-Years
22%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
-15%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Cash Equivalents
$9.3B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
5%
|
CAGR 10-Years
6%
|
|
|
Pfizer Inc
NYSE:PFE
|
Cash Equivalents
$2.9B
|
CAGR 3-Years
17%
|
CAGR 5-Years
8%
|
CAGR 10-Years
0%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Cash Equivalents
$5.6B
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
-10%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Cash Equivalents
$2.5B
|
CAGR 3-Years
-6%
|
CAGR 5-Years
4%
|
CAGR 10-Years
-4%
|
See Also
What is Prestige Consumer Healthcare Inc's Cash Equivalents?
Cash Equivalents
63.6m
USD
63.6m
USD
Based on the financial report for Dec 31, 2023, Prestige Consumer Healthcare Inc's Cash Equivalents amounts to 63.6m USD.
What is Prestige Consumer Healthcare Inc's Cash Equivalents growth rate?
Cash Equivalents CAGR 10Y
-4%
-4%
Over the last year, the Cash Equivalents growth was -26%. The average annual Cash Equivalents growth rates for Prestige Consumer Healthcare Inc have been 1% over the past three years , 21% over the past five years , and -4% over the past ten years .
You don't have any saved screeners yet
